Shenzhen Grid Core Bio-Technology Co., Ltd., known as Grid Core, has recently secured a seed-round financing of tens of millions of yuan. This funding was led by the Seed Fund of Shenzhen Capital Group, with additional support from Nanshan Strategic Emerging Industry Investment and Guangming Taino Seed Fund. The capital will primarily advance the research, development, and industrialization of Grid Core’s AI-driven high-throughput and ultrasensitive proteomics bioanalysis platform. It will also support the certification of related instruments and reagents and expand the company’s team and technology in drug development and clinical diagnosis.
Founded in June 2023 by experts in biochip material science, AI algorithms, and life-science instruments, Grid Core aims to integrate advanced semiconductor technology and AI into bioanalysis. The company’s goal is to provide efficient, accurate, and cost-effective solutions for life-science research, drug development, and clinical diagnosis, transitioning protein detection from traditional optics to semiconductor digitalization and AI.
Grid Core has developed numerous patents around its core technologies. Its technology is capable of detecting femtogram-level protein markers in blood samples, offering advantages in cost, stability, integration, and intelligence over foreign counterparts. A key innovation is the Integrated Surface Array Sensing System (ISAS), which uses on-chip fluorescence imaging to reduce costs and equipment size, potentially replacing traditional fluorescence microscopy.
The company has also achieved a global first by integrating microfluidic droplets, semiconductor imaging, and AI computational optics into its protein analysis platform. This ensures femtogram-level sensitivity and data consistency for long-term drug development and clinical trials.
With the new funding, Grid Core plans to enhance its ISAS system and develop an “AI intelligent bioanalysis brain” to improve noise reduction and automatic quality control. The platform’s applications will extend to drug research in neurodegenerative diseases, autoimmunity, and tumor immunity, providing comprehensive solutions from biomarker screening to diagnosis.
Founder Zhang Qingyang views this financing as a milestone, emphasizing the importance of integrating semiconductor and AI technologies in bioanalysis. The company aims to empower pharmaceutical companies and research institutions globally, contributing to precision medicine and drug development.
Investment partners recognize Grid Core’s potential for innovation and industrial breakthroughs, aligning with strategic goals to foster a first-class innovation ecosystem and a globally competitive brain-health platform.
